

Eveready Industries India Limited

Rising market share of alkaline batteries from ~6% to ~11%

In Q3 FY25, Eveready Industries India Limited (EIIL) delivered a topline growth of ~9% on a YoY basis, driven by high single-digit growth in the batteries segment and double-digit growth in the flashlight segment. However, gross margins contracted by 317 bps on a QoQ, primarily due to a sharp increase in raw material costs. Looking ahead, the flashlight segment is expected to sustain double-digit growth, supported by the enforcement of regulatory norms aimed at ensuring product safety, quality, and environmental protection. Additionally, the Company continues to witness robust momentum in its alkaline battery segment, with market share expanding significantly from ~6% to ~11%, reflecting strong traction in this category.

Capacity expansion

The Company is planning a capital expenditure of Rs. 1.8 Bn, primarily financed through borrowed funds (Rs. 1.5Bn), to establish a facility for producing 360 Mn units of AA and AAA alkaline batteries in response to the growing demand. Currently, the Company imports alkaline batteries, and domestic manufacturing is expected to yield a 10% cost savings. The anticipated asset turnover for this capacity is 1x. The facility is expected to commence in H2 FY26. The Company has purchased a land parcel in Jammu and Kashmir and for ~Rs. 200 Mn.

Change in regulation for flashlight segment

Effective January 1, 2025, the Ministry of Commerce has mandated that all flashlights sold in India must comply with Indian Standard IS 2083:2024. This regulation, enforced under the Bureau of Indian Standards (BIS) Act, 2016, aims to ensure product safety, quality, and environmental protection. This development is expected to create favorable growth opportunities for organized players as unorganized competitors may face challenges in meeting the required standards.

View & Valuation

We believe that EIIL would do a flat revenue growth in FY25E and improve its PAT margins from ~5% in FY24 to ~5.5% in FY26E due to the change in product mix. However, we believe that the market has discounted the benefits of operating leverage at the current price. Based on our estimates, we have maintained our 'NEUTRAL' rating with a target of Rs. 381 (35x FY26 earnings).

10th February 2025

NEUTRAL

CMP Rs. 358

TARGET Rs. 381 (6.4%)


Company Data


Bloomberg Code	EVRIN IN
MCAP (Rs. Mn)	26,022
O/S Shares (Mn)	73
52w High/Low	505/295
Face Value (in Rs.)	5
Liquidity (3M) (Rs. Mn)	~34

Shareholding Pattern %

	Dec 24	Sep 24	Jun 24
Promoters	43.2	43.2	43.2
FIIs	4.2	3.9	3.7
DIIs	2.8	2.6	2.6
Non- Institutional	49.8	50.3	50.5

Eveready vs Nifty





Source: Keynote Capitals Ltd.

Kev Financial Data

Rey i illalici	ai Data		
(Rs. Mn)	FY24	FY25E	FY26E
Revenue	13,143	13,130	14,088
EBITDA	1,404	1,444	1,332
Net Profit	668	746	791
Total Assets	8,024	9,384	11,029
ROCE (%)	19%	13%	13%
ROE (%)	19%	18%	16%

Source: Company, Keynote Capitals Ltd.

Karan Galaiya, Research Analyst Karan@keynotecapitals.net



Q3 FY25 Result Update

Result Highlights (Rs. In Mn)

Particulars	Q3 FY25	Q3 FY24	Change % (Y-o-Y)	Q2 FY25	Change % (Q-o-Q)	9M FY25	9M FY24	Change % (Y-o-Y)	FY24
Revenue from Operation	3,335	3,049	9%	3,626	-8%	10,455	10,334	1%	13,143
Gross Profit	1,457	1,349	8%	1,699	-14%	4,742	4,422	7%	5,679
Gross Profit %	43.7%	44.2%	-55 Bps	46.9%	-317 Bps	45.4%	42.8%	256 Bps	43.2%
Employee Cost	433	401	8%	434	0%	1,279	1,186	8%	1,604
Other Expenses	731	701	4%	788	-7%	2,195	2,089	5%	2,671
EBITDA	292	247	18%	478	-39%	1,268	1,148	10%	1,403
EBITDA %	8.8%	8.1%	67 Bps	13.2%	-442 Bps	12.1%	11.1%	102 Bps	10.7%
Depreciation	70	69	2%	72	-3%	217	212	2%	303
EBIT	222	178	25%	406	-45%	1,051	936	12%	1,101
EBIT %	6.7%	5.8%	82 Bps	11.2%	-453 Bps	10.0%	9.1%	99 Bps	8.4%
Finance Cost	66	79	-16%	63	5%	199	251	-21%	323
Other Income	3	4	-21%	7	-55%	12	33	-64%	29
PBT	159	103	54%	350	-55%	864	718	20%	806
Tax Expenses	28	19	48%	55	-48%	143	131	10%	139
PAT	131	84	56%	296	-56%	720	587	23%	668
EPS	1.80	1.16		4.07		9.91	8.08		9.19

Source: Company, Keynote Capitals Ltd.

Q3 FY25 Conference Call Takeaways

General Highlights

- Advertising expenditures for the quarter accounted for 11% of the Company's revenue.
- The Company has submitted an application for tax incentives related to its greenfield capital expenditure initiatives.
- The peak debt level following the completion of the capital expenditure is projected to be ~Rs. 3.3 Bn.
- The management guided that going forward, the sustainable gross margins are expected to be ~45%.

Flashlights

- During the quarter, the flashlight segment recorded an 18.9% growth on a YoY basis.
- Rechargeable flashlights demonstrated a robust growth of 55% on a YoY basis.
- The demand is being driven by innovative offerings such as the Siren Torch, various searchlights, and Kisan flashlights.
- The Company holds a dominant market share of 70% in the battery-operated flashlight segment.



Batteries

- The Company's market share in the alkaline battery segment increased from ~6% to ~11%.
- The Company is strategically focused on expanding its retail footprint in targeted markets to sustain and accelerate growth.
- Currently, gross margins for alkaline batteries stand at 20%. Post-commissioning of the new facility, gross margins are expected to improve significantly to ~28-30%.
- The Company holds a dominant market share of 53% in the overall battery industry.
- At the retail level, sales prices are as follows: carbon zinc batteries are priced at Rs. 10-12, premium carbon zinc batteries at Rs. 18, value alkaline batteries at Rs. 22, and premium alkaline batteries at Rs. 50.
- The target market for alkaline batteries is split equally between OEMs and retail (50:50), whereas Carbon Zinc batteries are predominantly (~100%) focused on the B2C segment.

Lighting

- Growth in the lighting segment moderated, impacted by ongoing value erosion, heightened competitive activity, and pricing pressures.
- The Company is prioritizing a dual distribution strategy, which includes expanding its presence in the electrical outlet segment through the onboarding of new dealers, while simultaneously strengthening its focus on alternative distribution channels.



Eveready Industries India Ltd | Quarterly Report

Financial Statement Analysis

Income Statement

income statement						Cash Flow Statement					
Y/E Mar, Rs. Mn	FY23	FY24	FY25E	FY26E	FY27E	Y/E Mar, Rs. Mn	FY23	FY24	FY25E	FY26E	FY27E
Net Sales	13,277	13,143	13,130	14,088	15,129	Pre-tax profit	347	807	1,039	1,198	1,286
Growth %		-1%	0%	7%	7%	Adjustments	1,041	529	628	754	827
Raw Material Expenses	8,267	7,464	7,353	7,819	8,396	Change in Working Capital	71	95	-139	-135	-177
Employee Expenses	1,466	1,604	1,720	1,803	1,936	Total Tax Paid	-516	109	-177	-204	-219
Other Expenses	2,443	2,671	2,613	2,747	2,950	Cash flow from operating Activities	943	1,539	1,351	1,612	1,716
EBITDA	1,101	1,404	1,444	1,719	1,846	Net Capital Expenditure	-243	-337	-900	-900	-325
Growth %		27%	3%	19%	7%	Change in investments	9	0	0	0	0
Margin%	8%	11%	11%	12%	12%	Other investing activities	984	108	30	30	30
Depreciation	274	303	313	387	427	Cash flow from investing activities	750	- 229	- 870	- 870	-295
EBIT	827	1,101	1,131	1,332	1,419	7	1.84	- 229 0	-870	-870	
Growth %		33%	3%	18%	7%	Equity raised / (repaid)					0
Margin%	6%	8%	9%	9%	9%	Debt raised / (repaid)	-2,408	-887	700	700	0
Interest Paid	566	323	252	399	434	Dividend (incl. tax)	-410	0	0	0	0
Other Income & exceptional	86	29	20	20	20	Other financing activities	-193	-382	-329	-399	-434
PBT	347	807	899	953	1,005	Cash flow from financing activities	-3,009	-1,268	371	301	-434
Tax	70	139	153	162	171	Net Change in cash	-1,316	42	852	1,044	988
Net Profit	276	668	746	791	834						
Growth %		142%	12%	6%	5%	Valuation Ratios					
Shares (Mn)	72.7	72.7	72.7	72.7	72.7	Y/E Mar, Rs. Mn	FY23	FY24	FY25E	FY26E	FY27E
EPS	3.80	9.19	10.27	10.88	11.48	Per Share Data					
						EPS	4	9	10	11	11
Balance Sheet						Growth %		142%	12%	6%	5%
Y/E Mar, Rs. Mn	FY23	FY24	FY25E	FY26E	FY27E	Book Value Per Share	44	53	63	74	86
Cash, Cash equivalents & Bank	71	81	1,424	1,806	2,464	Datama Datina					
Current Investments	0	0	0	0	0	Return Ratios					
Debtors	1,024	1,134	1,182	1,268	1,362	Return on Assets (%)	3%	8%	9%	8%	7%
Inventory	2,596	2,505	2,426	2,580	2,771	Return on Equity (%)	9%	19%	18%	16%	14%
Short Term Loans & Advances	776	5	5	5	5	Return on Capital Employed (%)	6%	19%	13%	13%	13%
Other Current Assets	164	914	914	914	914	Turnover Ratios					
Total Current Assets	4,631	4,638	5,950	6,573	7,515	Asset Turnover (x)	1.6	1.6	1.5	1.4	1.3
Net Block & CWIP	3,111	2,957	3,006	4,028	4,055	Sales / Gross Block (x)	2.9	2.7	2.6	2.4	2.2
Long Term Investments	75	75	75	75	75	Working Capital / Sales (x)	0%	4%	10%	16%	19%
Other Non-current Assets	999	353	353	353	353	Receivable Days	19	30	32	32	32
Total Assets	8,816	8,024	9,385	11,029	11,998	Inventory Days	110	125	122	117	116
						Payable Days	71	83	82	77	77
Creditors	1,672	1,686	1,600	1,754	1,889	Working Capital Days	59	72	72	72	71
Provision	211	164	164	164	164	Liquidity Ratios					
Short Term Borrowings	1,223	1,417	1,417	1,417	1,417	Current Ratio (x)	1.1	1.2	1.5	1.6	1.8
0.1 0 1.1.1.1.1	4 407	705	705	705	705	carrent natio (A)		1.2	1.5	1.0	1.0

Total Debt to Equity

Net Debt to Equity

Earnings Yield (%)

Price to Sales (x)

Price to Book (x)

0 EV/EBITDA (x)

EV/Sales (x)

Valuation

Interest Coverage Ratio (x)

1.6

1.0

1.0

76.9

1%

1.6

6.6

22.6

3.5

0.7

0.7

36.9

3%

1.9

6.4

17.6

4.6

0.8

0.5

34.9

3%

2.0

5.6

20.2

3.4

0.8

0.5

32.9

3%

1.8

4.8

17.0

3.3

0.7

0.3

31.2

3%

1.7

4.2

15.8

1.9

Cash Flow Statement

Source: Company, Keynote Capitals Ltd.

Other Current Liabilities

Total Current Liabilities

Deferred Tax Liabilities

Other Long Term Liabilities

Total Non Current Liabilities

Long Term Debt

Paid-up Capital

Reserves & Surplus

Shareholders' Equity

Non Controlling Interest

Total Equity & Liabilities

1,187

4.293

2,080

-1.620

869

1,329

2,831

3,194

8,816

0

363

705

3.972

1,435

-1.532

281

185

363

3,504

3,867

8,024

0

705

3.887

2,135

-1.532

281

885

363

4,250

4,613

9,385

0

705

4,175

2,835

-1,532

281 PE (x)

363

1,585

5,875

6,239

11,998

4 040

2,835

-1.532

281

363

1,585

5,041

5,404

11,029

0

KEYNOTE Rating History

Date	Rating	Market Price at Recommendation	Upside/Downside
4 th April 2024	BUY	339	+26.8%
29 th April 2024	BUY	356	+10.8%
6 th August 2024	NEUTRAL	409	+1.0%
14 th November 2024	NEUTRAL	360	+5.8%
10 th February 2025	NEUTRAL	358	+6.4%



Rating Methodology

Rating	Criteria			
BUY	Expected positive return of > 10% over 1-year horizon			
NEUTRAL	Expected positive return of > 0% to < 10% over 1-year horizon			
REDUCE	Expected return of < 0% to -10% over 1-year horizon			
SELL	Expected to fall by >10% over 1-year horizon			
NOT RATED (NR)/UNDER REVIEW (UR)/COVERAGE SUSPENDED (CS)	Not covered by Keynote Capitals Ltd/Rating & Fair value under Review/Keynote Capitals Ltd has suspended coverage			

Disclosures and Disclaimers

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Keynote Capitals Ltd. (KCL) is a SEBI Registered Research Analyst having registration no. INH000007997. KCL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. Details of associate entities of Keynote Capitals Limited are available on the website at https://www.keynotecapitals.com/associate-entities/

KCL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of KCL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

KCL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that KCL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

Details of pending Enquiry Proceedings of KCL are available on the website at https://www.keynotecapitals.com/pending-enquiry-proceedings/

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of KCL or its associates maintains arm's length distance with Research Team as all the activities are segregated from KCL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject KCL & its group companies to registration or licensing requirements within such jurisdictions. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

Specific Disclosure of Interest statement for subjected Scrip in this document:

Financial Interest of Research Entity [KCL] and its associates; Research Analyst and its Relatives	NO
Any other material conflict of interest at the time of publishing the research report by Research Entity [KCL] and its associates;	NO
Research Analyst and its Relatives Receipt of compensation by KCL or its Associate Companies from the subject company covered for in the last twelve months; Managing/co-managing public offering of securities in the last twelve months; Receipt of compensation towards Investment banking/merchant banking/brokerage services in the last twelve months; Products or services other than those above in connection with research report in the last twelve months; Compensation or other benefits from the subject company or third party in connection with the research report in the last twelve months.	NO
Whether covering analyst has served as an officer, director or employee of the subject company covered	NO
Whether the KCL and its associates has been engaged in market making activity of the Subject Company	NO
Whether the Research Entity [KCL] and its associates; Research Analyst and its Relatives, have actual/beneficial ownership of 1% or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance.	NO



The associates of KCL may have:

- financial interest in the subject company
- -actual/beneficial ownership of 1% or more securities in the subject company
- -received compensation/other benefits from the subject company in the past 12 months
- -other potential conflict of interests with respect to any recommendation and other related information and opinions.; however, the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of KCL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- -acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- -be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- -received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

The associates of KCL has not received any compensation or other benefits from third party in connection with the research report.

Above disclosures includes beneficial holdings lying in demat account of KCL which are opened for proprietary investments only. While calculating beneficial holdings, it does not consider demat accounts which are opened in name of KCL for other purposes (i.e. holding client securities, collaterals, error trades etc.). KCL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by KCL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of KCL. The report is based on the facts, figures and information that are believed to be true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. KCL will not treat recipients as customers by virtue of their receiving this report

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative product as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. KCL, its associates, their directors and the employees may from time to time, effect or have affected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. KCL, its associates, their directors and the employees may from time to time invest in any discretionary PMS/AIF Fund and those respective PMS/AIF Funds may affect or have effected any transaction in for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of KCL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject KCL to any registration or licensing requirement within such jurisdiction.



The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt KCL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold KCL or any of its affiliates or employees responsible for any such misuse and further agrees to hold KCL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

Keynote Capitals Limited (CIN: U67120MH1995PLC088172)

Compliance Officer: Mr. Jairaj Nair; Tel: 022-68266000; email id: jairaj@keynoteindia.net

Registered Office: 9th Floor, The Ruby, Senapati Bapat Marg, Dadar West, Mumbai – 400028, Maharashtra. Tel: 022 – 68266000.

SEBI Regn. Nos.: BSE / NSE (CASH / F&O / CD): INZ000241530; DP: CDSL- IN-DP-238-2016; Research Analyst: INH000007997

For any complaints email at kcl@keynoteindia.net

General Disclaimer: Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on www.keynotecapitals.com; Investment in securities market are subject to market risks, read all the related documents carefully before investing.